Search results
Unpacking the Latest Options Trading Trends in Eli Lilly and Co - Eli Lilly and Co (NYSE:LLY)
Benzinga· 5 hours agoLilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology. Current ...
Eli Lilly and Company (NYSE:LLY) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 6 hours agoEli Lilly and Company (NYSE:LLY) Q1 2024 Earnings Call Transcript April 30, 2024 Eli Lilly and...
Eli Lilly’s stock jumps as first-quarter profit tops estimates amid strong sales of Mounjaro,...
Market Watch· 2 days agoEli Lilly & Co. shares gained 7% premarket on Tuesday after the company reported first-quarter...
Eli Lilly's Weight-Loss Drug Still Going Strong, Boosts Annual Forecast
Benzinga via Yahoo Finance· 2 days agoThe volume increase was primarily driven by growth from Mounjaro, Zepbound, Verzenio, and Jardiance,...
Is Eli Lilly Stock A Buy After Weight-Loss Drug Crushes Quarterly Sales Forecasts?
Investor's Business Daily· 2 days agoTrulicity, another diabetes treatment, had $1.46 billion in first-quarter sales, down 26% and below...
Eli Lilly (LLY) Q1 Earnings Top, Sales Miss, 2024 View Raised
Zacks via Yahoo Finance· 2 days agoEli Lilly (LLY) beats first-quarter estimates for earnings but misses the same for sales. It raises...
Decoding Eli Lilly and Co (LLY): A Strategic SWOT Insight
GuruFocus.com via Yahoo Finance· 2 days agoThe financial overview indicates that LLY has experienced revenue growth driven by increased volume...
ETFs to Buy as Eli Lilly Beats Q1 Earnings, Lifts Outlook
Zacks via Yahoo Finance· 1 day agoEli Lilly and Company (LLY) raised its outlook for 2024 on rapidly climbing sales of the new obesity...
IBD Stock Of The Day Eli Lilly Surges After Weight-Loss Drug Obliterates Sales Views
Investor's Business Daily· 2 days agoHe kept his in-line (neutral) rating on Eli Lilly stock. Sales of other key products, cancer drug...
These 3 Companies Recently Lifted Guidance
Zacks via Yahoo Finance· 2 days agoRevenue throughout the period grew 26% year-over-year, driven by strong demand within Mounjaro, Zepbound, Verzenio, and Jardiance. The results impressed...
